139.18
Novartis Ag Adr (NVS) 最新ニュース
2 Top Stocks to Buy and Hold for the Long Term - Finviz
2 Top Stocks to Buy and Hold for the Long Term - The Motley Fool
Why Health Care ETFs Aren't Panicking Over Big Pharma's Price Cuts - Sahm
Pharma's $370B Bet on America: The ETF Plays for 2026 - Barchart.com
NVS Price History for Novartis Ag ADR Stock - Barchart.com
HSBC Lifts PT on Novartis AG (NVS) to $112 From $106 - Finviz
Immuno-oncology Clinical Trials Market Projected to Reach USD 23.63 Billion by 2032 at a CAGR of 12.37% - GlobeNewswire Inc.
Novartis (NVS) Enters $1.7 Billion Development Deal, Says Report - Insider Monkey
Novartis (NVS) enters $1.7 billion development deal, says report - MSN
Price Over Earnings Overview: Novartis - Sahm
13 Best ADR Stocks to Invest In - Insider Monkey
Novartis AG (NVS) Gets Upgraded to Overweight from Neutral by JPMorgan - Finviz
Novartis' Investigational Drug Reports Longer Disease Control In Patients With Rare Blood Disorder - Sahm
Novartis AG (NVS) Announces US FDA Approval of Itvisma - Finviz
Tiny Biotech Terns Takes Aim At Novartis' Leukemia Blockbuster - Sahm
Baird Financial Group Inc. Cuts Holdings in Novartis AG $NVS - Defense World
DoorDash Upgraded, Microsoft Downgraded: Updated Rankings on Top Blue-Chip Stocks - InvestorPlace
Ophthalmic Drugs Market Size to Cross USD 62.74 Billion by 2032, Driven by Advances in Eye Care Treatments and Rising Global Vision Disorders - GlobeNewswire Inc.
Free cash flow per share of Novartis AG Sponsored ADR – GETTEX:NOTA - TradingView
TD Cowen Says Novartis (NVS) Has Strong Growth Path Through 2029 - Finviz
Why Novartis Stock Topped the Market Today - sharewise.com
Novartis AG Common Stock (NYSE:NVS) Stock Quote - Markets Financial Content
FDA OKs Novartis SMA Treatment As First Gene Therapy Option For Kids, Teens And Adults - Sahm
Kepler Capital Keeps Their Buy Rating on Novartis AG (NOVN) - The Globe and Mail
NVS Ups Sales Projections as Key Drugs and Collaborations Fuel Growth - Finviz
Novartis Projects Faster Growth Through 2030 After Raising Drug Forecasts - Sahm
Morgan Stanley Upgrades Novartis (NVS) to Overweight, Raises Price Target to CHF 110 - Finviz
Is AI The Key To Beating Cancer? Why Pharma Stocks Are Soaring - Sahm
Net margin % of Novartis AG Sponsored ADR – HAM:NOTA - TradingView
Novartis' Phase III Malaria Study Meets Key Non-Inferiority Endpoint - Finviz
Novartis Issues $6 Billion in Debt Securities to Bolster Financial Strategy - The Globe and Mail
Stocks Generating Improved Relative Strength: Novartis ADR - Investor's Business Daily
大文字化:
|
ボリューム (24 時間):